Monday, January 6, 2014
Bankers and buysiders are not
expecting a repeat performance of biotech's stellar 2013. But the two dozen who
spoke with BioCentury say the capital markets are primed to open back up this
month, albeit on a more selective and price-sensitive basis.
The sector experienced a modest
slowdown during the latter portion of 2013 due to a combination of
profit-taking, deal fatigue and several high-profile setbacks that offered
generalist investors a useful reminder of biotech's inherent riskiness.